Melanie De Almeida
French Biotech Could Be Taking its Diabetes Drug to Phase III on its own
Immuno-oncology Pioneer Enters the Clinic with its RNA-based Therapy
New Immuno-oncology Biotech Gets a €20M Series A Funding Boost
Unexpected Side Effects: Are we Ready for the Rise of Immunotherapies?
Video Interview: Meet the Inventor of the Surgical Super-glue
Novartis Gains Access to Celyad’s allogenic CAR-T cell patents
This Dutch Biotech Could Boost Gene Editing of Primary Cells
BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy
Taking Biotech to the Next Level – How about Automation?
Novartis Negotiates its Way into the US Migraine Market
New Research could Save Patients from Graft-Versus-Host Disease
The World’s Most Expensive Drugs have European Owners
Labiotech UG, All Rights Reserved -
Send this to a friend